Treatment efficacy—specifically decreased migraine severity—served as the primary driver for patients when selecting a calcitonin gene-related peptide (CGRP) inhibitor for preventing migraine, according to findings published in Headache. Andrew Lloyd, DPhil, and colleagues assessed patient preferences regarding CGRP inhibitors for preventing migraine among 506 participants. Participants placed the most importance on a treatment’s ability to decrease migraine severity (mild vs unchanged severity; preference weight, β=1.65; P<0.001), followed by reliable treatment effectiveness (β=1.13; P<0.001) and a greater likelihood of decreased migraine frequency (β=1.00; P<0.001). Participants preferred an oral tablet every other day (β=1.00; P<0.001) to a quarterly infusion, quarterly injections (P=0.019), or a monthly injection (P<0.001). Preference for treatment characteristics were heterogeneous; subgroup analyses showed that participants naïve to CGRP monoclonal antibodies had a greater preference for oral therapy compared with those who had experience with the therapy (P=0.006).